Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Practical demonstration of time bias with administration of adjuvant therapy in lung cancer

  • Neil B. Newman
  • , Evan C. Osmundson

Producción científica: Articlerevisión exhaustiva

Resumen

Purpose/Background: Immortal time bias (ITB) can hinder appropriate interpretations of studies administering adjuvant therapies. Given the increase in National Cancer Data Base (NCDB) analyses evaluating postoperative radiation therapy (PORT) as an adjuvant therapy, we sought to practically demonstrate the effects of ITB by performing a series of simulated NCDB analyses. Methods: A simulated NCDB analysis was performed to examine how the reported benefit of PORT in stage III non-small cell lung cancer (NSCLC) may change with adjustment for ITB utilizing sequential land mark analysis (SLMA) and time dependent Cox (TDC) modeling. Results: On the simulation analysis of 6440 NSCLC patients, we found that the omission of PORT without ITB adjustment was associated with an increased risk of death (HR 1.17, p < 0.0001). After performing a sequential LMA, the detrmient of omitting PORT continued to decrease until it was no longer significant at 8 months, HR 1.05 (p = 0.09). With the TDC model, although still significant, the relative benefit of PORT decreased, to a HR of 1.07 (p = 0.02). Conclusions: Immortal time bias can alter the results of survival analyses if not carefully accounted for. Adjusting for this bias is essential for accurate data interpretation and to better quantify the impact and effect size of adjuvant therapies such as PORT.

Idioma originalEnglish (US)
Páginas (desde-hasta)75-78
Número de páginas4
PublicaciónLung Cancer
Volumen157
DOI
EstadoPublished - jul 2021
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Practical demonstration of time bias with administration of adjuvant therapy in lung cancer'. En conjunto forman una huella única.

Citar esto